Aptose Biosciences Inc. (APTOF)
OTCMKTS · Delayed Price · Currency is USD
2.310
0.00 (0.00%)
Apr 23, 2025, 4:00 PM EDT

Aptose Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-25.43-51.21-41.82-65.35-55.24
Upgrade
Depreciation & Amortization
0.40.470.530.620.61
Upgrade
Loss (Gain) From Sale of Assets
0.08-0.02--
Upgrade
Stock-Based Compensation
1.063.655.2112.9521.44
Upgrade
Other Operating Activities
-0.60.09-0.027.520.09
Upgrade
Change in Accounts Payable
-4.79-0.287.61-0.470.21
Upgrade
Change in Other Net Operating Assets
-6.72.69-3.841.43-1.01
Upgrade
Operating Cash Flow
-35.98-44.59-32.32-43.3-33.89
Upgrade
Capital Expenditures
-0.01-0.03-0.02-0.21-0.08
Upgrade
Sale of Property, Plant & Equipment
0.02----
Upgrade
Investment in Securities
-9.9930.09-3512.71
Upgrade
Investing Cash Flow
0.029.9630.07-35.2112.63
Upgrade
Long-Term Debt Issued
10----
Upgrade
Net Debt Issued (Repaid)
10----
Upgrade
Issuance of Common Stock
23.446.910.120.2358.98
Upgrade
Other Financing Activities
-0.02----0.17
Upgrade
Financing Cash Flow
33.416.910.120.2358.81
Upgrade
Foreign Exchange Rate Adjustments
-0-00.010.01
Upgrade
Net Cash Flow
-2.55-27.72-2.14-78.2837.55
Upgrade
Free Cash Flow
-35.98-44.62-32.35-43.52-33.97
Upgrade
Free Cash Flow Per Share
-51.48-198.17-157.76-219.81-186.79
Upgrade
Levered Free Cash Flow
-26.66-25.82-16.6-26.03-13.14
Upgrade
Unlevered Free Cash Flow
-26.53-25.82-16.6-26.03-13.14
Upgrade
Change in Net Working Capital
11.58-2.81-4.32-1.520.26
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.